Persistence of antibodies acquired by natural hepatitis E virus infection and effects of vaccination

作者:Su, Y. -Y.; Huang, S. -J.; Guo, M.; Zhao, J.; Yu, H.; He, W. -G.; Jiang, H. -M.; Wang, Y. -J.; Zhang, X. -F.; Cai, J. -P.; Yang, C. -L.; Wang, Z. -Z.; Zhu, F-C.; Wu, T.*; Zhang, J.*; Xia, N. -S.
来源:Clinical Microbiology and Infection, 2017, 23(5): 336.e1.
DOI:10.1016/j.cmi.2016.10.029

摘要

Objective: Naturally acquired anti-hepatitis E virus (HEV) immunity can protect against new HEV infections. The aim of this study was to analyse the persistence of naturally acquired anti-HEV immunoglobulin (Ig) G and anti-HEV IgG concentrations after vaccination. Methods: We examined the seropositivity rates of participants included in a phase 3 clinical efficacy trial (67 months' follow-up) for a HEV vaccine (Hecolin; Xiamen Innovax Biotech, China) and predicted long-term persistence using mixed-effect models. Results: The analysis focused on 2242 baseline seropositive participants in a control group (placebo recipients) and 2031 baseline seropositive participants in an vaccine group (vaccine recipients) who received 1 to 3 doses of Hecolin. Naturally acquired anti-HEV IgG levels decreased steadily independent of the initial antibody level; 50% of the placebo recipients were expected to have undetectable antibody concentrations after 14.5 years. After immunizationwith Hecolin, the power-law model and the modified power-law model predicted that 82.1 and 99.4% of the participants, respectively, would remain seropositive for anti-HEV IgG for 30 years after vaccination. Conclusions: Whereas naturally acquired anti-HEV IgG levels decrease steadily, HEV vaccination induces long-lasting, high-level anti-HEV IgG concentrations.

  • 出版日期2017-5
  • 单位厦门大学; 江苏省疾病预防控制中心